{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:40:11Z","timestamp":1756788011373,"version":"3.44.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Colorectal cancer is among the most common malignancies of the gastrointestinal tract. Immune checkpoint inhibitors (ICIs) have become a key component in the treatment of locally advanced rectal cancer (LARC), offering promising therapeutic outcomes. However, ICIs can occasionally cause significant adverse effects. Herein, we report a case of rectal cancer with suspected paraneoplastic myasthenia gravis (pMG) induced by immune checkpoint inhibitors (ICIs). Unfortunately, the patient lacked anti-acetylcholine receptor (AChR)\/muscle-specific kinase (MuSK) antibody testing and muscle biopsy, which precluded a definitive diagnosis of pMG. Remarkably, following surgical resection, the patient not only achieved complete tumor eradication but also experienced full remission of myasthenia gravis (MG).<\/jats:p>","DOI":"10.3389\/fonc.2025.1503362","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:14:01Z","timestamp":1756786441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical management of suspected paraneoplastic myasthenia gravis in rectal cancer during neoadjuvant immunotherapy: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhiyuan","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haining","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minglin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair Rectal Cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-center phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182299","article-title":"Locally advanced rectal cancer with dMMR\/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3728","article-title":"Mismatch repair\u2013deficient rectal cancer and resistance to neoadjuvant chemotherapy","volume":"26","author":"Cercek","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong","year":"2021","journal-title":"J Neurooncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11625-1","article-title":"Peripheral nervous system adverse events associated with immune checkpoint inhibitors","volume":"270","author":"Rossi","year":"2023","journal-title":"J Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.07.060","article-title":"Extrathymic Malignancies in a defined cohort of patients with myasthenia gravis","volume":"346","author":"Basta","year":"2014","journal-title":"J Neurol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.12.012","article-title":"Alopecia areata and myasthenia gravis presenting as paraneoplastic phenomena of breast cancer","volume":"21","author":"Dunn","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70143","article-title":"The association between myasthenia gravis and higher extrathymic cancer risk","volume":"15","author":"Khateb","year":"2025","journal-title":". Brain Behav"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2005.05.009","article-title":"Extrathymic Malignancies in patients with myasthenia gravis","volume":"237","author":"Levin","year":"2005","journal-title":"J Neurol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1443336","article-title":"Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report","volume":"59","author":"Nanni","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13889","article-title":"Myasthenia gravis related to small cell lung carcinoma","volume":"13","author":"L\u00f3pez-Vi\u00f1as","year":"2021","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00664","article-title":"Thymoma associated myasthenia gravis (TAMG): differential expression of functional pathways in relation to MG status in different thymoma histotypes","volume":"11","author":"Yamada","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":". Neurol Neuroimmunol Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023009","article-title":"Paraneoplastic syndromes involving the nervous system","volume":"349","author":"Darnell","year":"2003","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26166","article-title":"Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis","volume":"58","author":"Zekeridou","year":"2018","journal-title":"Muscle Nerve"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5223(03)00938-3","article-title":"The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer","volume":"126","author":"Okumura","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer","volume":"11","author":"Robert","year":"2020","journal-title":"Ther Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":". J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11864-023-01157-1","article-title":"Management of paraneoplastic syndromes in the era of immune checkpoint inhibitors","volume":"25","author":"Jean","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1055\/s-0043-1777353","article-title":"Updates in the management of paraneoplastic syndrome","volume":"44","author":"Verma","year":"2024","journal-title":"Semin Neurol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000123082.31092.53","article-title":"Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus","volume":"77","author":"Dean","year":"2004","journal-title":"Transplantation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-475X.2007.00232.x","article-title":"Surgical wound-healing complications in heart transplant recipients treated with rapamycin","volume":"15","author":"Zakliczynski","year":"2007","journal-title":"Wound Repair Regener"},{"key":"B40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1742-481X.2012.00950.x","article-title":"Effects of immunosuppressive therapy on wound healing","volume":"10","author":"Bootun","year":"2013","journal-title":"Int Wound J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1503362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:14:02Z","timestamp":1756786442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1503362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":40,"alternative-id":["10.3389\/fonc.2025.1503362"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1503362","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1503362"}}